BioAge Labs, Inc

BIOA · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

5.55USD-0.10 (-1.77%)

Price History

Full chart

Market Stats

Previous Close5.65

Open5.87

Day Range5.39 – 5.87

52-Week Range5.04 – 25.96

Volume427.40K

Market Cap330.92M

P/E (TTM)0.00

Forward P/E0.00

EPS-2.19

Dividend Yield0.00%

50-Day Avg12.39

200-Day Avg16.87

About

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEODr. Kristen Fortney Ph.D.
Employees60
Headquarters5885 Hollis Street, EmeryVille, CA, United States, 94608, USA
Websitehttps://bioagelabs.com

Leadership

Dr. Kristen Fortney Ph.D.Co-Founder, CEO, President, Treasurer, Secretary & Director · b. 1984
Dr. Eric Morgen M.D.Co-Founder, COO & Director · b. 1983
Dr. Paul D. Rubin M.D.Chief Medical Officer & Executive VP of Research · b. 1954
Dr. Dov A. Goldstein M.B.A., M.D.Chief Financial Officer · b. 1967
Mr. Shane Barton CPASenior Vice President of Finance & Accounting · b. 1971
Mr. Rusty Montgomery Ph.D.Senior Vice President of Research
Ms. Julie GammelgardSenior Vice President of People
Dr. Peng Leong M.B.A., Ph.D.Chief Business Officer & Therapeutic Area Head of Brain Aging
Mr. BJ Sullivan Ph.D.Chief Strategy Officer
Ms. Ann C. Neale RN BSNChief Development Officer

Financials

Income Statement

Currency: USD	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	2.67M	1.54M	2.17M	8.27M	14.94M	0	0	0	8.99M
Growth (%)	-	-42.10%	+40.76%	+280.88%	+80.63%	-100.00%	-	-	-
Cost of Revenue	2.69M	6.04M	2.61M	13.67M	22.32M	-	-	-	213.00K
Gross Profit	-23.78K	-4.50M	-440.83K	-5.39M	-7.38M	-	-	-	8.99M
Gross Margin	-0.89%	-291.68%	-20.30%	-65.21%	-49.39%	-	-	-	100.00%
Operating Expense	41.16M	30.70M	38.09M	24.24M	102.63M	-	-	-	101.78M
Operating Income	-41.18M	-35.20M	-38.53M	-29.63M	-110.01M	-39.97M	-48.40M	-78.19M	-92.78M
Operating Margin	-1545.08%	-2281.51%	-1773.92%	-358.17%	-736.22%	-	-	-	-1031.46%
EBITDA	-38.84M	-44.98M	-33.07M	-13.29M	-88.72M	-39.35M	-55.90M	-68.58M	-79.69M
EBITDA Margin	-1457.39%	-2914.99%	-1522.56%	-160.66%	-593.75%	-	-	-	-885.99%
Net Income	-33.22M	-46.42M	-37.23M	-22.48M	-98.15M	-39.72M	-63.85M	-71.11M	-80.61M
Net Income Margin	-1246.33%	-3008.45%	-1713.94%	-271.72%	-656.84%	-	-	-	-896.11%
R&D	16.58M	15.16M	20.29M	7.20M	5.47M	30.52M	33.89M	59.04M	73.97M
R&D as % of Total Revenue	622.05%	982.18%	933.98%	86.98%	36.59%	-	-	-	822.30%
Interest Expense	7.43M	-	-	-	-	241.00K	7.79M	2.37M	697.00K
Interest Expense % of Total Revenue	278.89%	-	-	-	-	-	-	-	7.75%

Balance Sheet

Currency: USD	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	114.08M	152.44M	143.09M	161.33M	69.51M	28.43M	25.92M	358.23M	294.89M
Total Liabilities	49.07M	94.91M	96.73M	112.84M	47.66M	140.99M	199.32M	35.11M	22.84M
Total Equity	65.01M	57.53M	46.36M	48.49M	21.85M	-112.56M	-173.40M	323.13M	272.05M
Cash	83.73M	51.04M	6.97M	16.16M	4.63M	27.64M	21.64M	354.35M	188.89M
Total Debt	29.73M	37.63M	40.09M	52.33M	37.62M	2.47M	53.25M	8.70M	5.56M
Net Debt	-54.00M	-13.41M	33.12M	36.17M	32.98M	-25.18M	31.61M	-345.64M	-183.33M

Cash Flow

Currency: USD	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-27.52M	-22.45M	-32.20M	-37.62M	-29.79M	-36.18M	-37.36M	-51.52M	-81.63M
Investing Cash Flow	-	-	-	-	-	-103.00K	-266.00K	-366.00K	-95.22M
Financing Cash Flow	99.92M	78.65M	54.89M	47.22M	18.85M	2.50M	34.94M	381.20M	11.47M
Capital Expenditure	12.79M	0	0	0	0	103.00K	166.00K	366.00K	719.00K
Free Cash Flow	-40.31M	-22.45M	-32.20M	-37.62M	-29.79M	-36.28M	-37.53M	-51.89M	-82.35M
FCF to OCF	146.46%	100.00%	100.00%	100.00%	100.00%	100.28%	100.44%	100.71%	100.88%

Earnings

Report Date	Aug 28, 2024	Nov 7, 2024	Mar 20, 2025	May 6, 2025	Aug 6, 2025	Nov 6, 2025	Mar 19, 2026	May 8, 2026	Aug 5, 2026	Nov 5, 2026
EPS Estimate	0.00	-0.73	-0.66	-0.53	-0.38	-0.51	-0.67	-0.71	-0.65	-0.66
EPS Actual	-0.60	-6.70	-1.00	-0.36	-0.60	-0.56	-0.72	-0.52	-0.58	-
Surprise	-	-817.81%	-52.67%	32.08%	-57.89%	-9.80%	-7.69%	26.76%	10.77%	-
Timing	-	After-hours	-	After-hours	After-hours	After-hours	-	Pre-market	After-hours	After-hours

Key Statistics & Ratios

Market Cap330.92M

Enterprise Value44.84M

Trailing P/E0.00

Forward P/E0.00

Price / Sales31.96

Price / Book0.96

EPS-2.19

Book Value8.19

Revenue (TTM)10.36M

Gross Profit (TTM)-77.43M

EBITDA-106.02M

Profit Margin0.00%

Operating Margin-1196.78%

Return on Equity-28.21%

Return on Assets-18.47%

Shares Outstanding45.90M

Shares Float39.19M

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Hold

Based on 4 analystsTarget 35.63

Hold
3
Strong Sell
1

Ownership Breakdown

Institutions: 90.56%
Insiders: 2.36%
Retail / Other: 7.08%

Top Institutional Holders

Cormorant Asset Management, LLC
2.89M6.30%
Sofinnova Ventures
2.29M5.00%
BlackRock Inc
2.27M4.94%
HHG PLC
2.09M4.56%
Octagon Capital Advisors LP
1.75M3.81%
MPM Oncology Impact Management LP
1.67M3.63%
RA Capital Management, LLC
1.65M3.60%
Vanguard Capital Management, LLC
1.35M2.95%
Balyasny Asset Management LLC
1.33M2.89%
BRAIDWELL LP
1.20M2.62%
Polar Capital Holdings PLC
1.13M2.47%
State Street Corp
850.89K1.85%
Sands Capital Ventures, LLC
786.35K1.71%
Geode Capital Management, LLC
749.27K1.63%
D. E. Shaw & Co LP
742.76K1.62%
Orbimed Advisors LLC
711.81K1.55%
StemPoint Capital LP
677.31K1.48%

Top Fund Holders

Vanguard MStar Total Stk Mkt Idx Invest
1.14M2.49%
Polar Capital Biotech S Inc
1.02M2.21%
iShares Russell 2000 ETF
901.85K1.96%